<DOC>
	<DOCNO>NCT00509236</DOCNO>
	<brief_summary>The purpose study compare sitagliptin glipizide lower blood sugar participant type-2 diabetes mellitus ( T2DM ) end-stage renal disease dialysis adequate glycemic control .</brief_summary>
	<brief_title>Sitagliptin Versus Glipizide Participants With Type 2 Diabetes Mellitus End-Stage Renal Disease ( MK-0431-073 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Participant T2DM . Participant dialysis day sign informed consent . Participant unlikely conceive us acceptable method birth control : hormonal contraceptive , intrauterine device ( IUD ) , diaphragm spermicide , contraceptive sponge , condom , vasectomy . Participant hemoglobin A1c ≥7 % ≤9 % measure within 2 week prior Visit 4/Week 2 . Participant ≥85 % compliant study medication singleblind placebo runin ( determined tablet/capsule count ) compliant diet , exercise runin treatment runin period . Participant history type 1 diabetes mellitus history ketoacidosis . Participant lose weight weight loss program maintenance phase ( define &lt; 2 kg weight loss 2 month ) , intend involved weight loss intervention outside prescribe study . Participant clinically significant hematological disorder ( e.g. , aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) . Participant cirrhosis active liver disease . Participant dialysis &lt; 6 month . Participant diagnose significant cardiovascular disorder new worsen sign symptom congestive heart failure within 3 month sign informed consent . Participant severe active peripheral vascular disease . Participant history malignancy ≤ 5 year prior sign inform consent , &gt; 5 year without documentation remission/cure . Participant treatment hyperthyroidism . Participant hypersensitivity contraindication glipizide .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>